@escolanolab.bsky.social
Our #WIN332 work is out! 🥳 rdcu.be/e15ti
In this study, led by Ignacio R. Relano, we report WIN332, the first engineered HIV-1 Env immunogen rationally designed to induce a new class of #TypeII #N332-glycan independent #V3-glycan antibodies. #THANKYOU to our collaborators for a great team effort!
In this study, led by Ignacio R. Relano, we report WIN332, the first engineered HIV-1 Env immunogen rationally designed to induce a new class of #TypeII #N332-glycan independent #V3-glycan antibodies. #THANKYOU to our collaborators for a great team effort!
Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates
Nature Immunology - WIN332 is an HIV-1 Env protein designed to elicit a new class of Asn332-glycan-independent antibodies (type II) to the V3-glycan site of Env. WIN332 immunization rapidly induces...
rdcu.be
February 3, 2026 at 12:37 PM
Our #WIN332 work is out! 🥳 rdcu.be/e15ti
In this study, led by Ignacio R. Relano, we report WIN332, the first engineered HIV-1 Env immunogen rationally designed to induce a new class of #TypeII #N332-glycan independent #V3-glycan antibodies. #THANKYOU to our collaborators for a great team effort!
In this study, led by Ignacio R. Relano, we report WIN332, the first engineered HIV-1 Env immunogen rationally designed to induce a new class of #TypeII #N332-glycan independent #V3-glycan antibodies. #THANKYOU to our collaborators for a great team effort!
Excited that our preprint is out! 💫 We report #WIN332, the first engineered HIV-1 Env immunogen rationally designed to elicit N332-and N334-glycan independent V3-glycan antibodies.
More ⬇️
www.biorxiv.org/content/10.1...
More ⬇️
www.biorxiv.org/content/10.1...
Rapid elicitation of a new class of neutralizing N332-glycan independent V3-glycan antibodies against HIV-1 in nonhuman primates.
Sequential immunization is a promising approach to elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 Envelope (Env). However, available protocols are inefficient and involve multiple im...
www.biorxiv.org
September 10, 2025 at 5:13 PM
Excited that our preprint is out! 💫 We report #WIN332, the first engineered HIV-1 Env immunogen rationally designed to elicit N332-and N334-glycan independent V3-glycan antibodies.
More ⬇️
www.biorxiv.org/content/10.1...
More ⬇️
www.biorxiv.org/content/10.1...
Excited to have presented our work on #WIN332, a new #HIV #vacccine candidate at the annual #CAVD meeting by the Gates Foundation in Tanzania. Even more excited to have spoken for the first time during a session moderated by one of my postdoctoral students, Maria Belen Palacio. Proud of you! 💫 😍
February 17, 2025 at 9:52 AM
Thank you to the Gates Foundation for featuring 4 of our studies at the annual #CAVD meeting in Tanzania. Congratulations Marta Tarquis Medina, Austin Kriews, Colby Agostino @colby-agostino.bsky.social and Ignacio Rodriguez Relaño, PhD for your Early Career Investigator awards, I am proud of you!
February 17, 2025 at 9:50 AM
Thank you to the Gates Foundation for featuring 4 of our studies at the annual #CAVD meeting in Tanzania. Congratulations Marta Tarquis Medina, Austin Kriews, Colby Agostino @colby-agostino.bsky.social and Ignacio Rodriguez Relaño, PhD for your Early Career Investigator awards, I am proud of you!